China Shineway Pharmaceutical
China Shineway Pharmaceutical Group Limited, commonly referred to as Shineway Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1997, the company has made significant strides in the development and manufacturing of traditional Chinese medicine and modern pharmaceuticals, with a strong operational presence across Asia and beyond. Shineway Pharmaceutical is renowned for its core products, including herbal medicines and innovative therapeutic solutions, which are distinguished by their quality and efficacy. The company has achieved notable milestones, such as receiving various certifications for its manufacturing processes, solidifying its reputation in the market. With a commitment to research and development, Shineway continues to enhance its product offerings, positioning itself as a leader in the pharmaceutical sector and contributing to the global healthcare landscape.
DitchCarbon Score
How does China Shineway Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Shineway Pharmaceutical's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Shineway Pharmaceutical's reported carbon emissions
In 2022, China Shineway Pharmaceutical, headquartered in CN, reported total carbon emissions of approximately 141,380,020 kg CO2e. This figure includes 87,499,000 kg CO2e from Scope 1 emissions, 30,190,000 kg CO2e from Scope 2, and 23,691,000 kg CO2e from Scope 3. The company has not disclosed specific reduction targets or initiatives, and there are no current commitments to the Science Based Targets initiative (SBTi) or other climate pledges. The emissions data for 2023 is not available, but the company has shown a consistent reporting pattern over the years. For instance, in 2021, total emissions were reported at 117,794,000 kg CO2e globally, with similar breakdowns across the scopes. The emissions data is cascaded from its parent company, China Shineway Pharmaceutical Group Limited, which provides a comprehensive view of the company's carbon footprint. Overall, while China Shineway Pharmaceutical has made strides in emissions reporting, it currently lacks defined reduction targets or commitments to industry-standard climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Scope 1 | 117,620,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 8,186,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 27,604,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Shineway Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
